Published in Lab Med on June 10, 2016
Molecular mechanisms of fibrinolysis. Br J Haematol (2005) 3.03
Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet (1987) 2.23
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem (1996) 2.13
The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem (1993) 1.94
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost (2008) 1.73
Plasminogen activator inhibitors--a review. Enzyme (1988) 1.53
Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost (1987) 1.44
Plasminogen activator inhibitor-1 4G/4G-genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost (1998) 1.43
Coagulation factor XIIIa is inactivated by plasmin. Blood (2015) 1.41
Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol (1988) 1.38
Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost (2003) 1.34
Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb (1991) 1.30
PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost (1997) 1.16
The existence of antifibrinolysin activity in platelets. Science (1953) 1.15
PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol (2000) 1.10
Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem (1984) 1.10
The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) (2002) 1.03
A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem (2004) 1.03
PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol (2002) 0.99
Factor XIII, clot structure, thrombosis. Thromb Res (2011) 0.95
Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem (1999) 0.94
PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol (1999) 0.92
Association of tissue plasminogen activator and plasminogen activator inhibitor polymorphism with myocardial infarction: a meta-analysis. Thromb Res (2012) 0.88
Fibrinolysis and the control of blood coagulation. Blood Rev (2014) 0.86
Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemost (1985) 0.84
The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism (2000) 0.84
The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost (2003) 0.84
The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J (1990) 0.83
Thrombosis of the deep cerebral veins with excessive bilateral infarction in a premature infant with the thrombogenic 4G/4G genotype of the plasminogen activator inhibitor-1. Eur J Pediatr (2000) 0.81
Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults. J Neurol (2012) 0.80
Fibrinolysis and the plasma carboxypeptidase. Curr Opin Hematol (1998) 0.80
Structure and expression of the human gene encoding plasminogen activator inhibitor, PAI-1. Gene (1989) 0.80
The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels. Cardiol Res Pract (2011) 0.79
Cerebral infarction and femoral venous thrombosis detected in a patient with diabetic ketoacidosis and heterozygous factor V Leiden G1691A and PAI-1 4G/5G mutations. J Pediatr Endocrinol Metab (2015) 0.77
Acute-phase response of human hepatocytes after infection with Chlamydia pneumoniae and cytomegalovirus. Eur J Clin Invest (2003) 0.77
Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Thromb (1993) 0.77
The 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene as an independent risk factor for placental insufficiency, which triggers fetal hemodynamic centralization. Ceska Gynekol (2015) 0.76
The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction. Dis Markers (2015) 0.76
Intraventricular hemorrhage in a full-term neonate associated with sinus venous thrombosis and homozygosity for the plasminogen activator inhibitor-1 4G/4G polymorphism. Pediatr Int (2003) 0.76